Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
I
schemic heart disease is the most important cause of morbidity and mortality in the developed world. Recent advances in revascularization of coronary arteries through percutaneous coronary intervention (PCI) and coronary artery bypass grafting have had a dramatic improvement in the fate of patients suffering with ischemic heart disease (1) . Nonetheless, revascularization does not address damage from ischemia-reperfusion (IR) injury and indeed may even contribute to it. For example, up to fifty percent of the final infarct size of an acute myocardial infarction is attributable to IR injury (2) . Additionally, IR injury is responsible for nonlethal effects, for example, myocardial stunning, arrhythmia and late remodeling. Therapies that reduce these detrimental effects of IR injury are desperately needed.
One promising target for cardioprotection is metabolic manipulation by optimizing use of myocardial glucose. The heart is an omnivore and can use a number of substrates for the generation of the adenosine triphosphate (ATP), required to power myocardial work. Glucose is the most efficient generator of ATP per unit of oxygen available (3) .
Therapies that increase glucose oxidation in preference to free fatty acids could reduce the impact of myocardial ischemia.
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone produced by the gut in response to food. It is primarily an insulinotropic hormone and has been extensively studied as a novel treatment for type 2 diabetes mellitus. It acts in a glucose-dependent manner, thus reducing the risk of Nordisk, Bagsvaerd, Denmark).
PRE-CLINICAL EVIDENCE OF GLP-1 CARDIOPROTECTION
GLP-1 protects cardiomyocytes from cell death.
In vitro, GLP-1 has been shown to avert cell death in HL-1 murine adult cardiomyocytes treated with the pro-apoptotic agent staurosporine (15) . Both wildtype and GLP-1R homozygous knockout mice experienced cardioprotection from GLP-1-(7-36) and -(9-36),
suggesting the protective effect occurred independent of receptor binding (16) . GLP-1 protection was similarly associated with reduced activation of proapoptotic molecules in rats, and occurred regardless of whether it was given prior to ischemia or in early reperfusion (17, 18) . In vivo, GLP-1 infusion given to dogs with pacing-induced cardiomyopathy improved left ventricular function with systemic changes such as reduced heart rate and blood pressure (19) . Finally, the pathways of ischemic preconditioning may be activated to increase cellular resistance to IR injury. These pathways may overlap, limiting lethal and nonlethal IR injury to various extents. Figure 1 offers an overview of a number of proposed mechanisms for GLP-1-mediated cardioprotection. Evidence for these mechanisms is reviewed below.
MYOCARDIAL GLUCOSE UTILIZATION. A change in myocardial glucose utilization is consistent with the physiological role of an incretin hormone. Fatty acids are the main fuel for energy production in the heart (26) , although the omnivorous myocyte will use a number of different sources for ATP production (3).
Glucose is the most oxygen-efficient source of ATP and is the preferred substrate when insulin and glucose levels are high, as in the post-prandial state (27) . Glucose is preferentially metabolized in ischemic Patients treated with exenatide during ST-segment elevation myocardial infarction (STEMI) had reduced infarct size by 15% on cardiac magnetic resonance imaging, although it failed to alter peak troponin levels or left ventricular ejection fraction assessed at 90 days (70) . Of note, all the benefit seen in that study occurred in patients with short ischemic times (71).
Further study of 58 primary PCI patients treated with 
